Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Markus Wartenberg

Markus Wartenberg


Engagements in different organisations/initiatives:

  • Das Lebenshaus e.V.: Senior Manager GIST/Sarcomas (www.daslebenshaus.org)
  • Das Wissenshaus GmbH - Institute of Oncology: Executive Director
  • Sarcoma Patients EuroNet e.V. (SPAEN): Chair/President (www.sarcoma-patients.eu)
  • IKCC: Advisor/Mgmt-Services to the IKCC Board of Directors (www.ikcc.org)
  • Member of the ESMO PAWG (Patient Advocacy Working Group)
  • Involved in Rare Cancers Europe, New Horizons GIST, The German Sarcoma Conference and other nat. & intl. “Advisory Boards” and “Steering Committees”

Markus is a honorary Senior Manager of the charitable patient advocacy organization Das Lebenshaus e.V.
(= The House of Life) This is a German non-profit organization - supporting patients with rare solid tumors: GIST, Sarcomas, Kidney Cancer. He is responsible for conceiving and organizing all community activities in GIST/Sarcomas with a small team of patients, employees and freelancers. After his commercial education in the industry, he completed his studies as a specialist in journalism & communication. He worked in several different German communication and PR-agencies as a consultant and creative director for national and international brands. In 1993 he founded his own agency, which had a focus on pharmaceutical, medical and health communication. After 10 years with his business, he left the agency in 2003 to start a more meaningful life in founding and managing the charitable patient association Das Lebenshaus e.V. (House of Life) and the non-profit-company Das Wissenshaus GmbH (House of Knowledge). Markus maintains extensive collaborations with leading Sarcoma experts (centers), industry and other important stakeholders to improve the situation of sarcoma- and GIST-patients in Germany and other European countries. This includes e.g. early involvement in clinical trials, timely and correct diagnosis, access to qualified treatment, monitoring, guidelines, centers of excellence, generating more/better evidence/data and HTA-processes.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings